LAS VEGAS, October 30, 2018 /PRNewswire/ --
Triple Negative Breast Cancer is defined as a heterogeneous breastcancer phenotype where the estrogen and progesterone receptor are negative, and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization
(Logo: https://mma.prnewswire.com/media/776895/DelveInsight_Logo.jpg )
According to DelveInsight's assessment - based on data from recent studies and registries - shows that China accounted for 43% of the total diagnosed incident cases, followed by the US for 24% of these cases, out of all TNBC cases in G8 countries in 2016. Amongst the EU-5 countries, Germany had the highest diagnosed incidence (32%) of TNBC in the year 2016 while Spain was accountable for the least number of TNBC incident cases.
Click here to get a Webex demo: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)---Market-Insight,-Epidemiology-and-Market-Forecast-2027
Moving on to the market outlook of the disease, the therapeutic market for TNBC in G8 Countries is expected to increase at a CAGR of 18.9% by 2027, for the study period 2016-2027. Currently, the therapeutic market size of metastic TNBC (mTNBC) in the United States is mainly held by the systemic chemotherapies (either alone or in combination), such as Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, and Docetaxel, among others. These chemotherapies are being used off-label, both in first line as well as in second line treatment settings of TNBC patients, with variation in the dosing frequency and drug-combinations. The United States accounts for the largest market size of TNBC, in comparison to the other G8 countries i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), Japan, and China. The country held a USD 84 Million market share in 2016 and this share is expected to increase by 2027.
Recently, Lynparza (Olaparib; AstraZeneca), a poly ADP ribose polymerase (PARP) inhibitor, became the first non-chemotherapy treatment for patients with an inherited BRCA mutation (also known as gBRCA or germline BRCA) and HER2-negative metastatic breast cancer, to receive the U.S. Food and Drugs Administration (USFDA) approval. Although the drug is not specifically approved for TNBC patients, it still provides a novel treatment option for mTNBC patients with BRCA mutation.
The total market size of TNBC is accounted by the market revenue generated by 1st Line of Therapy (LoT) and 2nd LoT. Upcoming therapies, such as Sacituzumab Govitecan (Immunomedics) in 2019, Pembrolizumab (Roche), Niraparib (Tesaro) and Rucuparib (Clovis Oncology) have the potential to create a significant positive shift in the TNBC market size during the study period (2016-2027). The launch of Sacituzumab Govitecan in US and EU will have a significant impact on the overall market. The drug will fill the void created by unavailability of targeted therapies and is expected to capture the market easily.
This report provides a detailed overview of the triple negative breast cancer and in-depth understanding of the historical and forecasted epidemiology. Additionally, it highlights the existing treatment patterns, potential upcoming drugs along with identifying the best of the market opportunities through provision of the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2027.
Click here to get a sample report: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)---Market-Insight,-Epidemiology-and-Market-Forecast-2027
Reasons to buy this report:
Key Topics Covered:
1. Key Insights 2. TNBC Market Overview at a Glance 2.1. Market Share (%) Distribution of TNBC in 2016 2.2. Market Share (%) Distribution of TNBC in 2027 3. Disease Background and Overview: TNBC 4. Unmet Needs 5. Epidemiology and Patient Population 6. Country Wise-Epidemiology of TNBC 6.1. The United States 6.2. EU5 Countries 6.3. United Kingdom 6.4. Japan 6.5. China 7. Treatment Practices 8. Marketed Drug Analysis 8.1. Lynparza: AstraZeneca 8.1.1. Drug Description 8.1.2. Regulatory Milestones 8.1.3. Clinical Development 8.1.4. Safety and Efficacy 8.1.5. Product Profile 9. Emerging Therapies 9.1. Emerging Drugs Analysis 9.2. Atezolizumab: Roche 9.3. Pembrolizumab: Merck
9.4. Ipatasertib: Roche 9.5. Enzalutamide: Pfizer/Astellas 9.6. Cobimetinib: Hoffman La Roche 9.7. Rucaparib: Clovis Oncology 9.8. Niraparib: Tesaro 9.9. Capivasertib: AstraZeneca 10. TNBC: G8 Countries Market Analysis 11. Market Outlook by Country 12. Market Drivers 13. Market Barriers 14. Appendix 15. DelveInsight Capabilities 16. Disclaimer 17. About DelveInsight
Click here for free demo of the report
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us: Shruti Thakur firstname.lastname@example.org +91-9650213330
SOURCE DelveInsight Business Research, LLP
Subscribe to our Free Newsletters!